Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from MAIA Biotechnology, Inc. ( (MAIA) ).
On July 9, 2025, MAIA Biotechnology announced the dosing of the first patient in Taiwan for the expansion phase of its THIO-101 Phase 2 trial, targeting advanced non-small cell lung cancer (NSCLC). This expansion marks a significant milestone, broadening the patient pool and potentially positioning MAIA for a first-mover advantage in a multibillion-dollar market. The trial evaluates ateganosine in patients who have failed previous treatments, with promising median overall survival results of 17.8 months compared to the typical 5-6 months in similar settings.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company’s lead program, THIO, is a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 349,593
Technical Sentiment Signal: Hold
Current Market Cap: $55.46M
For detailed information about MAIA stock, go to TipRanks’ Stock Analysis page.